Regeneron Pharmaceuticals (REGN)
EBITDA Margin
37.01%
TTM · Period ending:
REGN EBITDA Margin
Latest reported37.01%period ending
Latest reported37.01%period ending
REGN TTM EBITDA Margin (-66.00% → 37.01%)
TTM ebitda margin
High-resolution chart · PNG
REGN ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| 37.0139% | |
| 38.5057% | |
| 40.565% | |
| 40.0925% | |
| 38.1414% | |
| 39.2433% | |
| 37.4454% | |
| 39.7332% | |
| 37.8632% | |
| 34.7226% | |
| 35.7797% | |
| 37.0809% | |
| 41.3573% | |
| 41.1167% | |
| 43.2075% | |
| 46.7491% | |
| 47.064% | |
| 57.4463% | |
| 60.1635% | |
| 61.8656% | |
| 61.0323% | |
| 51.1807% | |
| 48.2894% | |
| 47.2794% | |
| 47.3536% | |
| 39.862% | |
| 40.71% | |
| 36.9246% | |
| 35.0781% | |
| 41.1834% | |
| 40.6797% | |
| 40.8288% | |
| 40.7834% | |
| 39.563% | |
| 38.3006% | |
| 36.6931% | |
| 34.5422% | |
| 31.3128% | |
| 29.4894% | |
| 27.8311% | |
| 28.7382% | |
| 31.1058% | |
| 32.3322% | |
| 34.2116% | |
| 31.9873% | |
| 31.3918% | |
| 30.4854% | |
| 32.4618% | |
| 36.1707% | |
| 36.5458% | |
| 38.1349% | |
| 38.5089% | |
| 40.2228% | |
| 39.6098% | |
| 36.03% | |
| 27.985% | |
| 5.5748% | |
| -18.8067% | |
| -38.2501% | |
| -30.3206% | |
| -25.1706% | |
| -17.9744% | |
| -16.4163% | |
| -24.802% | |
| -17.4481% | |
| -16.9545% | |
| -16.6494% | |
| -16.2209% | |
| -25.9508% | |
| -30.2433% | |
| -30.3828% | |
| -22.4116% | |
| -36.303% | |
| -51.4059% | |
| -82.3578% | |
| -176.1353% | |
| -176.9471% | |
| -173.7118% | |
| -146.6783% | |
| 227.1847% | |
| 217.0603% | |
| 214.8615% | |
| 211.3894% | |
| -78.6363% | |
| -44.7118% | |
| -26.1728% | |
| 8.4549% | |
| -4.05% | |
| -16.2925% | |
| -34.186% | |
| -148.141% | |
| -250.5236% | |
| -359.6591% | |
| -428.2309% | |
| -516.1906% | |
| -506.1135% | |
| -492.6929% | |
| -434.0032% | |
| -321.7054% | |
| -150.9985% |